UK markets open in 1 hour 13 minutes
  • NIKKEI 225

    29,151.18
    +550.77 (+1.93%)
     
  • HANG SENG

    26,037.84
    -94.19 (-0.36%)
     
  • CRUDE OIL

    83.63
    -0.13 (-0.16%)
     
  • GOLD FUTURES

    1,805.20
    -1.60 (-0.09%)
     
  • DOW

    35,741.15
    +64.13 (+0.18%)
     
  • BTC-GBP

    45,401.36
    +125.32 (+0.28%)
     
  • CMC Crypto 200

    1,501.89
    +1,259.21 (+518.88%)
     
  • ^IXIC

    15,226.71
    +136.51 (+0.90%)
     
  • ^FTAS

    4,117.93
    +9.02 (+0.22%)
     

Is Cara Therapeutics Stock a Buy After Its First FDA Drug Approval

·3-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Cara Therapeutics (NASDAQ: CARA) recently scored a key win with Food and Drug Administration approval of Korsuva in treating pruritis associated with chronic kidney disease for patients on hemodialysis. In this Motley Fool Live video recorded on Aug. 25, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not Cara stock is a buy after the big news. Another biotech had some good news on the FDA front: Cara Therapeutics, ticker there is CARA, and its partner Vifor Pharma (OTC: GNHAY) announced on Monday that the FDA had approved Korsuva for trading moderate to severe pruritus associated with chronic kidney disease, and this is in adults undergoing dialysis.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting